Abstract 23P
Background
This modified Delphi consensus addresses practical gaps in genetic counselling and testing, risk assessment, and management of germline BRCA mutations (gBRCAm)-associated breast cancer (BC) in the Asia-Pacific region.
Methods
An expert panel of 16 medical oncologists, geneticists, and breast surgeons from the Asia-Pacific region arrived at 58 statements. The level of consensus of statements was considered at ≥75%. A survey of 134 healthcare practitioners (HCPs) (medical oncologists, geneticists, and breast surgeons) explored the real-world practices in the Asia-Pacific region.
Results
About 85% of the statements (49/58) reached a consensus and concorded with international guidelines. A significant discrepancy was observed between expert recommendations and real-world HCPs’ practice (Table). The consensus endorsed gBRCAm and gPALB2m testing in HR+/HER2- early (e) BC, high-risk identification guided by clinical trial criteria based on physician discretion and preferred adjuvant endocrine therapy (ET) + poly (ADP-ribose) polymerase inhibitors (PARPi) over ET + cyclin-dependent kinase 4 and 6 inhibitors in gBRCAm carriers with high-risk HR+/HER2- eBC cases. Table: 23P
Expert recommendations and real-world practice
Statements | Experts (%) | HCPs (%) |
Implementing pretest genetic counselling by nongeneticists after receiving proper training. | 87.5 | 48.5 |
Including CPS + EG scores in the risk assessment tools. | 67.9 | 87.4 |
Discussing contralateral risk-reducing mastectomy in gBRCAm patients | 87.5 | 41.8 |
Considering PARPi administration concurrently or sequentially with IO in BRCAm eTNBC cases who do not achieve a pathological complete response following neoadjuvant chemotherapy + IO. | 84.6 | 50 |
CPS+EG: Clinical and pathologic stage; IO: Immunotherapy; m: Mutation.
Conclusions
Streamlined genetic testing (GT) for BRCAm TNBC patients should be considered irrespective of age at diagnosis or family history. Prioritisation for GT for BRCAm HR+/HER2- eBC who may be eligible for adjuvant PARPi is needed in the real world, where resources are limited. The oncology community must recognise and address these practice gaps by improving access to resources and education.
Clinical trial identification
Editorial acknowledgement
Professional editorial assistance in the writing of the abstract was provided by BioQuest Solutions Pte Ltd and funded by AstraZeneca UK Limited in accordance with Good Publication Practice (GPP) guidelines 2022.
Legal entity responsible for the study
AstraZeneca UK Limited.
Funding
AstraZeneca UK Limited.
Disclosure
S.C. Lee: Financial Interests, Personal, Advisory Board, Advisory board, speaker invitations: Pfizer, Novartis, AstraZeneca, Roche, MSD; Financial Interests, Personal, Advisory Board, Advisory Board: Eli Lilly; Financial Interests, Institutional, Research Grant: Pfizer, ACT Genomics, Eisai, Taiho, MSD, Karyopharm, ASLAN Pharmaceuticals; Financial Interests, Institutional, Local PI: Roche, Novartis, Daiichi sankyo, BMS, AstraZeneca; Financial Interests, Personal, Steering Committee Member: AstraZeneca. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo; Financial Interests, Institutional, Other, Research Grant: AstraZeneca, Pfizer, Roche, MSD; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Lilly, Pfizer, Novartis, MSD, Roche, Daiichi Sankyo; Financial Interests, Institutional, Writing Engagement: Pfizer. C. Singer: Financial Interests, Personal, Other, consultancy: Amgen; Financial Interests, Personal, Advisory Board, advisory function: Novartis; Financial Interests, Personal, Advisory Board, ADVISORY ROLE: Roche; Financial Interests, Personal, Other, STUDY SUPPORT: Pfizer; Financial Interests, Personal, Advisory Board, ADVISORY, Speaker HOnoraries, study support: AstraZeneca; Financial Interests, Personal, Coordinating PI, study coordinator: Amgen; Non-Financial Interests, Personal, Principal Investigator, Study: Amgen, AstraZeneca; Non-Financial Interests, Personal, Project Lead, register: Pfizer. J. Balmaña: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer; Financial Interests, Institutional, Local PI: Pfizer, MedSir; Financial Interests, Institutional, Steering Committee Member: AstraZeneca. V.K. Tan: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche. N.A.M. Sari: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AstraZeneca; Financial Interests, Institutional, Speaker, Consultant, Advisor: Pfizer, MSD, Novartis. M. Md Yusof: Financial Interests, Institutional, Advisory Board, disease and treatment indications advisory board or expert committee meeting, as panellist or chair or speaker: AstraZeneca, Specialsed Therapeutics, Roche, MSD, Pfizer, Novartis, Eli Lily, Eisai; Financial Interests, Institutional, Invited Speaker, disease and treatment indications -speaker: Amgen; Financial Interests, Institutional, Invited Speaker, invited speaker for local conferences: Zuellig Pharma; Financial Interests, Institutional, Invited Speaker, speaker: Mundi Pharma, GSK; Financial Interests, Institutional, Other, speaker for doctors only platform webinar: Docquity; Financial Interests, Personal and Institutional, Local PI, KEYNOTE 119, KEYNOTE 355, KEYNOTE B49, KEYNOTE4280A, KEYNOTE 076: MSD; Financial Interests, Personal, Advisory Board, advisory board member for amivantamab in exon 20 insertion tve cancer: Johnson and Johnson; Financial Interests, Personal, Ownership Interest, surgery and oncology centre small partnership: Integrated Oncology Centre ( Kuala Lumpur) Sdn Bhd; Financial Interests, Personal and Institutional, Funding, local funding for multicentre data collection and reporting: Mundi Pharma; Financial Interests, Personal and Institutional, Local PI, Compleement1, EPIKB3, CANOPY-A: Novartis; Financial Interests, Personal and Institutional, Local PI, CAPITELLO, L-MOCA, ADAURA-A, SERENA-4: AstraZeneca; Financial Interests, Personal and Institutional, Local PI, GLOW study: Astellas; Financial Interests, Personal and Institutional, Local PI, ARc -10 study: ARCUS 10; Non-Financial Interests, Personal, Leadership Role, secretary: Malaysian Oncological Society; Non-Financial Interests, Personal, Advisory Role, clinician advisor: Breast Cancer women association ( NGO), KANWORK ( NGO); Non-Financial Interests, Personal, Advisory Role, government led group to evaluate the cost effectiveness of neoadjuvant anti HER2 therapy: Health Technology Assessment Trastuzumab in neoadjuvant treatment early breast cancer; Non-Financial Interests, Personal, Advisory Role, Clinical Practice Guideline for Breast Cancer 2020-2021: Ministry of Health Malaysia; Non-Financial Interests, Personal, Advisory Role, Specialty Education Subcommittee: Malaysian Medical Council Malaysia; Non-Financial Interests, Personal, Principal Investigator, PALOMA-3 trial: Johnson and Johnson. F.V.F. Que: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Camber, GMT, Kalbe, Novartis, Roche; Financial Interests, Institutional, Advisory Board: Novartis. Y. Lu: Financial Interests, Personal, Advisory Board: Novartis, Eli Lilly, MSD, Roche, Pfizer, AstraZeneca, Eisai, Daiichii Sankyo, Gilead; Financial Interests, Institutional, Local PI: Novartis, Roche, Pfizer, MSD, Eli Lily, Eisai, AstraZeneca, Gilead, Jellox; Non-Financial Interests, Personal, Leadership Role, Chair or co-chair of steering committee of clinical trials: Novartis. N. Parinyanitikul: Financial Interests, Institutional, Speaker, Consultant, Advisor: MSD, Roche, AstraZeneca, Lilly, Novartis, Eisai, Pfizer. C.P. Pham: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, MSD, BI, Roche. N.A.M. Taib: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Zuellig Pharma; Financial Interests, Institutional, Research Grant: AstraZeneca. Y. Antill: Financial Interests, Institutional, Research Grant: MSD, GSK, AstraZeneca, Eisai; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, GSK, AstraZeneca, Lilly; Financial Interests, Personal and Institutional, Advisory Board: MSD, GSK, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract